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This report aims to describe, for the first time in the
literature, the use of transoral robotic surgery (TORS)
associated with sentinel lymph node biopsy (SLNB), as well
as to discuss the advantages and disadvantages of the two
techniques when used separately or simultaneously. Tech-
nological developments in the medical field have led to
amazing progress in surgery, and with the objective to
perform a less invasive procedure with minimal complica-
tions and allow the early discharge of patients, the da Vinci
System was introduced by Intuitive Surgical (Sunnyvale, CA,
USA) in 1999. Since then, the number of robotic surgical
devices has increased, demonstrating numerous advantages
over conventional surgery, for example, fine precision and
freedom of movement. TORS has emerged as the newest
surgical alternative for the treatment of oropharyngeal
squamous cell carcinoma (OPSCC) and has been growing
steadily in popularity. TORS was first described in the
literature in 2006 by Weinstein’s team at the University of
Pennsylvania for its successful use in animals, cadavers, and
then in clinical practice, initially on oropharyngeal tumors
and then on supraglottic tumors. In OPSCC, it is possible to
use TORS for T1-2 tumors, but this kind of cancer can lead to
precocious neck micrometastasis, which occurs in approxi-
mately 30% of patients with cN0 of the neck. Due to this
probability, a prophylactic neck dissection is indicated;
however, this is usually performed two weeks before the
TORS procedure; therefore, the patient needs two admissions
and two surgical procedures with anesthesia, and in 70% of
the cases, no lymph node metastases are found. Moreover,
there are some possible complications associated with the
neck dissection, such as hematoma, spinal nerve palsy and
lymphatic fistula. Because of these possibilities, three years
ago, our group started to perform the SLNB of oral and
oropharyngeal cancers with the same technique as that
performed for melanoma or breast cancer. In patients with
T1-2 N0 OPSCC, the TORS protocol along with simultaneous
SLNB was introduced in order to minimize the side effects
and the cost of this kind of surgery (1-3).
’ METHODS
This study was approved from by the Ethics and Research
Committee of the Faculty of Medicine of the Sao Paulo
University (no. 438/13).
A consecutive, nonrandomized cohort of 40 patients
were included in this study to evaluate the TORS method
and whether SLNB could be performed. All patients had
histopathologically diagnosed squamous cell carcinoma of
the upper head and neck region and had neither regional
metastases in cervical lymph nodes (cN0) nor distant
metastases (cM0) as determined by clinical or radiological
methods.
The patients were placed under an orbiter camera, and
topical anesthesia (10% lidocaine) was applied to their
pharyngeal mucosa. Four peritumoral injections of 40 MBq
technetium-99m (99Tec) nanocolloid dissolved in 0.2 ml of
physiological saline solution were administered. The first
dynamic scan sequence of 60 ten-second frames started
immediately after the injection. This was followed by a
second sequence of 120-second frames for 30 min. In addition,
5-minute scans were conducted from the anterior and lateral
aspects on both sides after 30, 60 and 120 min (Figure 1). After
the dynamic scan sequences were completed and a SPECT/
CT was performed (Figure 2), the sentinel lymph nodes
(SLNs) were located using a gamma probe, and their positions
were marked on the skin (3,4).
The day after SLN detection, we primarily performed
the oropharyngeal tumor resection with TORS (a radical
tonsillectomy). Then, we confirmed the location of the SLNs
by using the gamma probe, which analyzed the uptake
signal. After that, we made an incision and performed the
lymph node resection. To confirm that the SLN was resected,
the gamma probe signal on the bed of the surgical area
should have diminished. Then, the sample was submitted for
histopathological examination (3,4).DOI: 10.6061/clinics/2018/e550s
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In accordance with international standards, the SLNs were
then fixed in 10% formalin and embedded in paraffin. The
tissues were then cut into sections of 150 mm and stained
with hematoxylin and eosin (3,4).
Case report
AASM is a 60-year-old female born in Boa Viagem, CE,
Brazil and living in Diadema, SP and is a retired farmer. At
the first consultation in July 2015, the patient had a one-year
history of progressive dysphagia and sore throat. She had a
smoking history of 50 pack-years, but quit one month before
the appointment. She used to consume alcohol but stopped
6 months prior, and she has used a dental prosthesis for
40 years. At the physical exam, there was a reddened lesion
involving the soft palate that was more prominent on the
uvula and both anterior and posterior right pillars. There
were no palpable cervical masses. Upon endoscopy, there
was no involvement of the larynx or nasopharynx. Biopsy
of the lesion on 07.16.2015 showed in situ squamous cell
carcinoma. The face, neck and chest CT scan on 08.12.15
showed a thickening area and asymmetrical enhancement of
the right soft palate, extending to the left tonsillar fossa and
uvula. There were no suspicious cervical lymph nodes. The
diagnosis was OPSCC, clinically staged as cT1 N0 M0.
On 10.02.2015, the patient underwent TORS, with the
successful excision of a left tonsillar fossa tumor, with free
frozen section margins. Simultaneous SLNB was performed
with no complications. The final pathology report showed a
moderately differentiated squamous cell carcinoma located
on the left tonsillar fossa, with 1.2 cm in its greatest diameter
and 0.3 cm thickness with free margins. No angiolymphatic
or perineural invasion were found. Lymph node metastasis
was identified in one of two SLNs removed with the left level
II dissection. The final pathological staging was pT1 pNs1
M0. On 11.26.2015, the patient underwent a left modified
radical neck dissection and a right elective selective neck
dissection of levels I, II and III, because the lesion extended
beyond midline. The pathological report found no additional
metastatic lymph nodes. The patient had a great outcome
after both surgeries without any complication. The hospital
stay was short. and the follow-up period was uneventful.
’ DISCUSSION
The first description of TORS was made in 2006 by
Weinstein et al. at the University of Pennsylvania. Currently,
TORS is widely used in head and neck surgery, especially for
the surgical treatment of oropharyngeal cancers. Advantages
include the avoidance of external incisions, improved func-
tional outcomes, a reduced need for tracheostomy and
gastrostomy, decreased blood loss, and shorter hospital
stays (5,6). The main disadvantage of robotic surgery is the
high financial cost, especially in developing countries (7).
Robotic selective neck dissection via the postauricular facelift
approach may be used for patients with clinically staged N0
tumors; however, this procedure should be strictly reserved for
patients for whom cosmetic satisfaction is important because of
its significantly increased operating time and cost (8,9). This
technique is not routinely preformed in our environment.
To our knowledge, this is the first case reported in the
literature in which combined TORS and open minimally
invasive surgical technique (SLNB) was employed. The
immediate follow-up period was uneventful; however, it is
still impossible to evaluate the long term oncologic outcome of
this patient. Nevertheless, the advantages of both minimally
invasive techniques were achieved in the present case. SLNB is
a reliable staging tool for T1/T2 cN0 OPSCC, without adverse
effect on patient survival and with fewer complications. No
late recurrences occurred in long-term follow-up. Close
follow-up is mandatory for SN+ patients, who are at higher
risk of nodal recurrence and have worse prognosis (3).
This is the first report of the combined, simultaneous use
of two minimally invasive techniques, TORS and SLNB, in
a patient with oropharyngeal cancer, with encouraging
initial results.
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Figure 1 - Dynamic scan sequence of 120-second frames for 30 min
following the injection of 99Tec. Right tonsillar tumor with a
sentinel lymph node at level II on the right side.
Figure 2 - SPECT/CT and lymphoscintigraphy fusion. Right tonsillar
tumor with a sentinel lymph node at level II on the right side.
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